Insider Transaction Report for Cadrenal Therapeutics, Inc.

This filing details insider transactions for Cadrenal Therapeutics, Inc. (CVKD). Reporting owner Pham Quang X, Chairman, CEO and Interim CFO, reported the sale of 2,127 shares of common stock on June 25, 2026, at a price of $3.00 per share, and 9,029 shares on June 26, 2026, at a weighted average price of $3.05 (ranging from $3.00 to $3.18). These sales were conducted under a Rule 10b5-1 trading arrangement. Following these transactions, Pham Quang X directly holds 105,989 shares. Additionally, The PVBQ Living Trust, of which Pham Quang X is Trustee, holds 200,000 shares indirectly, with his child as the beneficiary. The reporting owner is a 10% owner, director, and officer.